Market news
MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.
Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0.65. See our latest analysis for Alto Neuroscience. Alto Neuroscience’s latest quarterly loss lands against a backdrop of rapid share price gains, with a 90 day share price return of 47.43% and a year to date share price return of 93.73%, suggesting strong recent momentum. The 1 year total...
Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with basic loss per share from continuing operations of US$0.65 and US$1.34, respectively. Despite these larger losses, analysts have maintained a strongly positive stance on Alto Neuroscience, highlighting the progress of its clinical-stage pipeline targeting bipolar depression and major depressive...
Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last 12 months, Alto Neuroscience has returned about 9.2x an initial investment, which raises the hurdle for any new buyers who are sensitive to valuation. The expanded development of ALTO-207 and the recent funding that is expected to support operations for several years can help underpin growth...
Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.
Alto Neuroscience (ANRO) has an average rating of buy and mean price target of $37.11, according to
MOUNTAIN VIEW, Calif., August 12, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.
MOUNTAIN VIEW, Calif., July 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to
This is the newest page. Registered accounts read further back.